Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.5220
+0.0021 (0.40%)
At close: Nov 13, 2026, 4:00 PM EST
0.5200
-0.0020 (-0.38%)
Pre-market: Nov 16, 2026, 4:20 AM EST
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
17.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 31.75M |
| Lipocine | 3.74M |
| IGC Pharma | 1.11M |
| Cocrystal Pharma | 330.00K |
| aTyr Pharma | 190.00K |
KTTA News
- 2 days ago - Pasithea Therapeutics price target raised to $4 from $3 at H.C. Wainwright - TheFly
- 2 days ago - Pasithea Therapeutics Quarterly report: Q3 2026 - Filings
- 3 days ago - Pasithea Therapeutics presents clinical data from PAS-004-103 study - TheFly
- 3 days ago - Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference - GlobeNewsWire
- 11 days ago - Pasithea Therapeutics Transcript: KOL event - Transcripts
- 12 days ago - Pasithea gets FDA clearance for Phase 2 PAS-004 trial in skin neurofibromas - TheFly
- 12 days ago - Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF) - GlobeNewsWire
- 18 days ago - Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026 - GlobeNewsWire